[go: up one dir, main page]

CN107709332A - 一种c,o‑螺环芳基糖苷类化合物及其制备和应用 - Google Patents

一种c,o‑螺环芳基糖苷类化合物及其制备和应用 Download PDF

Info

Publication number
CN107709332A
CN107709332A CN201680037415.3A CN201680037415A CN107709332A CN 107709332 A CN107709332 A CN 107709332A CN 201680037415 A CN201680037415 A CN 201680037415A CN 107709332 A CN107709332 A CN 107709332A
Authority
CN
China
Prior art keywords
methyl
group
bromo
oxy
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680037415.3A
Other languages
English (en)
Other versions
CN107709332B (zh
Inventor
柳红
李佳
王江
李静雅
陈辉
李丹
李建
王冰
王一冰
蒋华良
陈凯先
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN107709332A publication Critical patent/CN107709332A/zh
Application granted granted Critical
Publication of CN107709332B publication Critical patent/CN107709332B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明提供了一种C，O‑螺环芳基糖苷类化合物及其制备和应用，具体地，本发明提供了一种如下式(I)所示的化合物。其中，各基团的定义如说明书中所述。所述的化合物可以作为SGLT2抑制剂，用于制备治疗糖尿病、动脉粥样硬化、肥胖症等疾病的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201680037415.3A 2015-06-23 2016-06-23 一种c,o-螺环芳基糖苷类化合物及其制备和应用 Active CN107709332B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015103538434 2015-06-23
CN201510353843.4A CN106317068A (zh) 2015-06-23 2015-06-23 一种c,o-螺环芳基糖苷类化合物及其制备和应用
PCT/CN2016/086892 WO2016206604A1 (zh) 2015-06-23 2016-06-23 一种c, o-螺环芳基糖苷类化合物及其制备和应用

Publications (2)

Publication Number Publication Date
CN107709332A true CN107709332A (zh) 2018-02-16
CN107709332B CN107709332B (zh) 2019-12-20

Family

ID=57584713

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510353843.4A Pending CN106317068A (zh) 2015-06-23 2015-06-23 一种c,o-螺环芳基糖苷类化合物及其制备和应用
CN201680037415.3A Active CN107709332B (zh) 2015-06-23 2016-06-23 一种c,o-螺环芳基糖苷类化合物及其制备和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510353843.4A Pending CN106317068A (zh) 2015-06-23 2015-06-23 一种c,o-螺环芳基糖苷类化合物及其制备和应用

Country Status (11)

Country Link
US (1) US10550143B2 (zh)
EP (1) EP3315502B1 (zh)
JP (1) JP6644814B2 (zh)
KR (1) KR102130155B1 (zh)
CN (2) CN106317068A (zh)
AU (1) AU2016282151B2 (zh)
BR (1) BR112017027762A2 (zh)
CA (1) CA3002878C (zh)
HK (1) HK1249898A1 (zh)
RU (1) RU2746858C2 (zh)
WO (1) WO2016206604A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113429379A (zh) * 2021-06-28 2021-09-24 江苏法安德医药科技有限公司 一种lh-1801中间体及其制备方法和应用
CN118047784A (zh) * 2022-10-13 2024-05-17 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112661736B (zh) * 2021-01-12 2021-09-28 广州市力鑫药业有限公司 一种泰格列净中间体的合成方法
CN112645915B (zh) * 2021-01-13 2021-10-08 广州安岩仁医药科技有限公司 一种sglt2抑制剂中间体的合成方法
CN115819398B (zh) * 2022-10-31 2024-06-14 江苏联环药业股份有限公司 一类sglt2抑制剂关键中间体及其制备方法和应用
CN117050126A (zh) * 2023-08-15 2023-11-14 南京华威医药科技集团有限公司 一种新的托格列净关键异构体制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111508A (zh) * 2005-01-28 2008-01-23 中外制药株式会社 螺缩酮衍生物及其作为糖尿病治疗药物的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5230613B2 (ja) * 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
TWI403516B (zh) * 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
CN101812043A (zh) * 2009-02-19 2010-08-25 上海恒瑞医药有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101111508A (zh) * 2005-01-28 2008-01-23 中外制药株式会社 螺缩酮衍生物及其作为糖尿病治疗药物的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113429379A (zh) * 2021-06-28 2021-09-24 江苏法安德医药科技有限公司 一种lh-1801中间体及其制备方法和应用
CN118047784A (zh) * 2022-10-13 2024-05-17 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物

Also Published As

Publication number Publication date
EP3315502A1 (en) 2018-05-02
RU2018102590A (ru) 2019-07-23
AU2016282151A1 (en) 2018-02-15
US20180305390A1 (en) 2018-10-25
RU2746858C2 (ru) 2021-04-21
US10550143B2 (en) 2020-02-04
JP6644814B2 (ja) 2020-02-12
HK1249898A1 (zh) 2018-11-16
KR20180020276A (ko) 2018-02-27
CA3002878A1 (en) 2016-12-29
CN107709332B (zh) 2019-12-20
EP3315502B1 (en) 2024-07-31
EP3315502A4 (en) 2019-03-20
KR102130155B1 (ko) 2020-07-03
JP2018520141A (ja) 2018-07-26
CA3002878C (en) 2020-08-04
BR112017027762A2 (zh) 2018-11-06
RU2018102590A3 (zh) 2019-07-24
CN106317068A (zh) 2017-01-11
AU2016282151B2 (en) 2019-07-11
WO2016206604A1 (zh) 2016-12-29

Similar Documents

Publication Publication Date Title
CN107709332A (zh) 一种c,o‑螺环芳基糖苷类化合物及其制备和应用
EP2070926A1 (en) 13,13a-DIHYDROBERBERINE DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITION AND USE
EP3207928B1 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
JP2012153726A (ja) 新規３−ヒドロキシ−５−アリールイソチアゾール誘導体
CN110072861A (zh) 用于治疗疾病的二取代吡唑类化合物
CN103159755B (zh) 一种α-糖苷酶抑制剂的制备方法和用途
CN111303030B (zh) 一种吖啶二酮类化合物在制备抗糖尿病药物中的应用
JP2016500096A (ja) ナトリウム−ヨウ素シンポータの新規阻害剤
US20230303569A1 (en) Heterocyclic compounds as therapeutic agents
TWI824251B (zh) 吡啶嗎啉類化合物、其製備方法及其應用
CN110903224A (zh) 一种芳基磺酰胺类化合物、其制备方法、药物组合物及用途
RU2833479C1 (ru) Соединение пентациклического тритерпенового гликозида, способ его получения и применения
CN108623555B (zh) 一种苯并氧杂䓬类化合物、及其制备方法和药物组合物与用途
CN113896757B (zh) 一类五环三萜类碳苷化合物及其制备方法和用途
CN107303298B (zh) 一种苯[g]杂芳基并[a,g]喹嗪类化合物的药物用途及其制备方法
CN102086197B (zh) 具胰岛素增敏活性的原小檗碱衍生物及用途
EP4538263A1 (en) Novel tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing said compound, and use thereof
CN102503894B (zh) 5-取代亚甲基咪唑烷-2,4-二酮类衍生物及其药物组合物与应用
CN113272276A (zh) N-酰基磺酰胺盐类FBPase抑制剂、其制备方法、药物组合物及用途
CN106349211B (zh) 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用
CN119431362A (zh) 取代杂芳基羧酸类化合物及其制法和药物用途
CN113354616A (zh) 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN112826821A (zh) 别嘌呤醇类衍生物在制备预防和/或治疗糖尿病的药物中的用途
CN102875567B (zh) 一类含哌嗪化合物、制备及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1249898

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20180216

Assignee: JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd.

Assignor: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Contract record no.: X2020980003768

Denomination of invention: C.I.dye red 176, C.I.dye red 185 and C.I.dye yellow 83 preparation method

Granted publication date: 20191220

License type: Exclusive License

Record date: 20200703

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1249898

Country of ref document: HK